**7. Conclusion**

BRAF V600E mutations are present in 7–10% of CRC. It represents a population with poor prognosis and a particular clinical phenotype, being more prevalent in

**45**

**Author details**

Lee-Jen Luu1,2 and Timothy J. Price3,4\*

2 Royal Adelaide Hospital, Adelaide, Australia

4 University of Adelaide, Adelaide, Australia

3 The Queen Elizabeth Hospital, Woodville, Australia

\*Address all correspondence to: timothy.price@sa.gov.au

1 Adelaide Oncology and Haematology, North Adelaide, Australia

provided the original work is properly cited.

*BRAF Mutation and Its Importance in Colorectal Cancer*

remains important to improve outcomes in BRAF MT CRC.

women, older than 70 years of age, associated with poorly differentiated histology and right-sided tumours. Chemotherapy with the addition of anti-angiogenesis agent remains the current standard of care in the first line metastatic setting. More aggressive, triplet chemotherapy (FOLFOXIRI) may be appropriate in the selected patient. BRAF inhibition has been extensively investigated for second line therapy and beyond and when in combination with EGFR, MEK and PI3K inhibitors have increased response rates, however, PFS and OS remains poor. Ongoing research

*DOI: http://dx.doi.org/10.5772/intechopen.82571*

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,
